The selling pressure regarding Sanofi shares could subside shortly. In fact, the support area that is currently being tested around 79.69 EUR has come into play and could, at least in the short term, keep the downside pressure at bay. Investors have an opportunity to buy the stock and target the € 88.7.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
In a short-term perspective, the company has interesting fundamentals.
The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 78.51 EUR in weekly data.
Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 79.69 support.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company is in a robust financial situation considering its net cash and margin position.
The company's attractive earnings multiples are brought to light by a P/E ratio at 13.09 for the current year.
This company will be of major interest to investors in search of a high dividend stock.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 78.51 EUR
According to forecast, a sluggish sales growth is expected for the next fiscal years.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.